2 Atlantic Avenue
Boston, MA 02110
Telephone: 617-722-6099
Facsimile: 617-725-3267
E-mail: [email protected]
Website: lehmanmillet.com

Quick Facts

Account wins 9
Account losses 2
Active business clients 20
Brands by 2013 sales  
Brand-product accounts held 22
$25 million or less 7
$25 million – $50 million 2
$50 million – $100 million 3
$100 million – $500 million 4
$500 million to $1 billion 4
$1 billion or more 2
Services Mix  
Strategic planning 20%
Alternative media 15%
Medical communications      15%
Sales materials 15%
Consumer media 10%
Journal advertising 10%
Convention/exhibits 5%
Direct marketing 5%
Professional relations 5%

Client Roster

Abbott Animal Health
Abbott Diagnostics
AcelRx Pharmaceuticals
Alnylam Pharmaceuticals
Ariad Pharmaceuticals
Bausch & Lomb
Exact Sciences
Genomic Health
Infinity Pharmaceuticals
Intuitive Surgical
Multiple Myeloma Research Foundation
Sunovion Pharmaceuticals
Zimmer Dental

2013 marked a milestone for LehmanMillet as the agency said goodbye to founder Bruce Lehman – arguably the longest standing CEO of a health care advertising agency and a true visionary. President Carolyn Morgan, previously managing director of the West Coast office, has taken on leadership of the full organization with her characteristic focus and energetic spirit.

The Year’s Accomplishments

The smooth transition of leadership was just one highlight in a very successful year for LehmanMillet. The agency added prelaunch agency of record assignments from AbbVie for ABT-719, for the prevention of post-surgical acute kidney injury, and AcelRx Pharmaceuticals for Zalviso, a patient-controlled Pez-like pain management device with sufentanil; Infinity Pharmaceuticals’ IPI-145, a targeted therapy in indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia; a campaign to raise awareness for Medtronic’s non-leaded surgical suite; a launch campaign for NuPathe’sZecuity, a migraine patch; agency of record for Toshiba America Medical Systems’ imaging franchise; and trial branding and Website work for Verastem’sdefactinib.

“Each new account represents an important building block in the agency’s continued commitment to working with companies seeking to change the standard of care,” executives remark.

As the agency continues on its growth trajectory, executives say they are laser-focused on protecting the quality of the work. “To this end, we have promoted from within and reached outside to enrich the talent of the agency,” they comment.

Deborah Lotterman, a 16-year veteran, was promoted to chief creative officer – ensuring high-caliber work – from strategic development to creative execution, is consistent across all lines of business. Kate Booth has been with the agency for four years and has stepped up to the new role of VP of strategy, working to ensure clients leverage the opportunities and confront the challenges inherent in the competitive set and the larger market landscape. New to the agency are Marc Pondel, Ph.D., medical director, and Greg Reiser, VP of accounts. Pondel will research and propose clinical points of view, guide scientific platform development, and foster agency and client clinical education. Reiser will lead accounts for the Santa Ana book of business, bringing years of expertise and experience to the table.

Notable awards won by LehmanMillet in 2013 include a nomination in the Med Ad News Manny Awards for Most Creative Agency; a Greatest Creators award from PM360 for Meda Pharmaceuticals and a PM360 Trailblazer Award for Auxilium Pharmaceuticals’ “Ask About the Curve” as the Best Unbranded Campaign; and a Gold in the Web Health Awards for Abbott Laboratories/Abbott Diagnostics’ “Factoring in the Human” Website.

Structure And Services

With six client-facing departments – accounts, planning, strategy, medical, digital, and creative – executives say the agency is, at its core, militant “in a fun way.” Each department brings unique talents and insights to clients’ strategic initiatives and resulting creative output.

“Whether we are working on scientific platforms, clinical trial recruitment, pre-launch, launch activities, repositioning or life-cycle management, we measure all efforts against the brief, composed of well-defined objectives and a singular message designed to move our target audience – health care professionals, patients and consumers – to action,” executives say. “This fierce commitment to the brief – developed with insights from all departments and critical input from our clients – has enabled us to deliver successful outcomes time and again. We continue to see demand and growth coming from our planning, strategy, medical and digital teams. While creative and accounts are our foundation, we believe investment in these additional four teams is the key to our future offerings and continued growth.”

Future Plans

LehmanMillet executives say they are excited for the next chapter in the agency’s long-running story. Plans include growing by 50 percent in the next three years, moving the Boston offices to accommodate that growth, and ensuring staff and clients are continually thriving. “We seek continuous improvement in developing our leadership, and creating an environment that encourages creativity and great work is essential to our livelihood,” executives say. “There is always better, and we are committed to finding it, for our team and our clients.”


The agency continues its ongoing relationships with Lifebox and MedtechWomen. Lifebox is dedicated to preserving and protecting the health of patients worldwide by providing surgical equipment and support services in low resource and lower-middle income countries at no or reduced cost. LehmanMillet provides strategic and creative services at no cost and the agency is proud of the small part it plays in making surgeries safer the world over. MedtechWomen is an organization dedicated to highlighting women’s leadership in the medtech industry. “LehmanMillet contributes to the effort with strategic and creative services for the annual event and is excited to continue to support this industry’s group of impressive female leadership,” executives say.